Marksans Pharma Limited (NSE: MARKSANS) to acquire 100% of QliniQ B.V., enhancing its presence in European markets.
Wockhardt Limited (WOCKPHARMA) receives U.S. FDA approval for ZAYNICH™, a novel antibiotic for treating complicated urinary tract infections.
Anlon Healthcare Limited (AHCL) reports 43% revenue growth and 48% EBITDA surge in Q4 FY26, driven by strategic acquisitions and robust R&D.
Lupin Limited (NSE: LUPIN) secures U.S. FDA approval for Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets, marking a significant milestone.
Max India Limited (MAXIND) reports Q4FY26 revenue up 44%, strong growth in residences, services, and AGEasy.
Zydus Lifesciences Limited (ZYDUSLIFE) receives US FDA Priority Review for Saroglitazar NDA to treat Primary Biliary Cholangitis (PBC).
Indoco Remedies Limited (INDOCO) receives EU GMP certification for its Baddi Plant III, underscoring commitment to high-quality pharmaceutical manufacturing.
Themis Medicare Limited (THEMISMED) reports Q4 FY26 results with revenue up 6.7% YoY and PAT turning positive.
CORONA Remedies Limited (CORONA) secures EU-GMP accreditation for its Hormone and Oral Solid Dosage facilities, boosting its global market expansion.
Dr. Reddy's Laboratories Ltd. (NSE: DRREDDY) to celebrate 25 years on NYSE with Closing Bell ceremony.